Objectives: Azole resistance in Aspergillus fumigatus isolates has been increasingly reported with variable prevalence worldwide and is challenging the effective management of aspergillosis. Here we report the coexistence of both TR₃₄/L98H and TR₄₆/Y121F/T289A resistance mechanisms in azole-resistant A. fumigatus (ARAF) isolates originating from Tanzania, Africa.
Methods: A total of 30 soil and woody debris samples from the surroundings of Kilimanjaro Christian Medical Centre, Moshi, Tanzania, were processed for detection of ARAF isolates and were investigated for susceptibility to itraconazole, voriconazole, posaconazole and isavuconazole. All ARAF isolates were subjected to a real-time PCR assay for detection of mutations and were genotyped by microsatellite typing.
Results: Of the 30 samples, 29 yielded 108 A. fumigatus isolates. Overall, 15 ARAF isolates were obtained, which included 4 ARAF harbouring the TR₄₆/Y121F/T289A mutation and 11 isolates carrying TR₃₄/L98H. All four TR₄₆/Y121F/T289A A. fumigatus isolates showed high MICs of voriconazole (>16 mg/L) and isavuconazole (8 mg/L). In contrast, the 11 TR₃₄/L98H A. fumigatus isolates were pan-azole resistant. The isolates were cross-resistant to azole fungicides. Notably, 20% of environmental samples harboured ARAF and the TR₄₆/Y121F/T289A resistance mechanism was found in 5.5% of the soil samples, where it coexisted with TR₃₄/L98H. The Tanzanian TR₄₆/Y121F/T289A strains had a genotype identical to Dutch clinical TR₄₆/Y121F/T289A isolates.
Conclusions: The present study reports the isolation of resistant A. fumigatus strains harbouring the TR₄₆/Y121F/T289A mutation from Africa. Recovery of TR₄₆/Y121F/T289A from the environment is worrisome and we must strive for effective surveillance of clinical and environmental sources to detect azole resistance in A. fumigatus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dku259 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The proteomic response of to amphotericin B (AmB) reveals the involvement of the RTA-like protein RtaA in AmB resistance.
Microlife
December 2024
Department of Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (HKI), Adolf-Reichwein-Str. 23, 07745 Jena, Germany.
The polyene antimycotic amphotericin B (AmB) and its liposomal formulation AmBisome belong to the treatment options of invasive aspergillosis caused by . Increasing resistance to AmB in clinical isolates of species is a growing concern, but mechanisms of AmB resistance remain unclear. In this study, we conducted a proteomic analysis of exposed to sublethal concentrations of AmB and AmBisome.
View Article and Find Full Text PDFChronic pulmonary aspergillosis in tea population of Assam.
PLoS Negl Trop Dis
January 2025
Department of Radiology, Assam Medical College & Hospital, Dibrugarh, Assam, India.
Background: Chronic pulmonary aspergillosis (CPA) is a disease commonly caused by Aspergillus fumigatus and other Aspergillus species characterized by cavitary lung lesions. Tea garden population is an agrarian population of Assam, mostly associated with tea plantations. Assam is a major tea-producing state with 803 tea gardens producing approximately 50% of the total tea in India, of which 177 are present in the Dibrugarh district alone.
View Article and Find Full Text PDFRespiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.
Lung
January 2025
Mother and Child Department, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Purpose: The study evaluated the effects of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in people with cystic fibrosis (pwCF) and a clinical history of Aspergillus fumigatus (AF) infection.
Methods: This prospective cohort study included pwCF who initiated ETI therapy and had received antifungal treatment in the preceding five years due to allergic bronchopulmonary aspergillosis (ABPA group) or other AF-related clinical manifestations (AF group). A control group of pwCF with no prior respiratory cultures positive for AF was also included.
Statistical optimization of pectinases from thermophilic Aspergillus fumigatus BT-4 employing response surface methodology through submerged fermentation using agricultural wastes.
BMC Biotechnol
January 2025
School of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, China.
Background: In this study, thermophilic pectinase-producing strains were isolated. Among all the isolates, strain No. 4 was identified as Aspergillus fumigatus BT-4 based on its morphology and 18 S rDNA analysis.
View Article and Find Full Text PDFTwo different diseases in two adolescent girls with the same clinic: Allergic bronchopulmonary aspergillosis.
Tuberk Toraks
December 2024
Division of Pediatric Pulmonology, Department of Pediatrics, Ankara University Faculty of Medicine, Ankara, Türkiye.
Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction observed in asthma as well as cystic fibrosis (CF) patients due to the colonization of the airways by Aspergillus fumigatus. While ABPA is most commonly observed in CF patients (2-9%), it is seen at a rate of 1-2% in patients diagnosed with asthma. ABPA is mostly seen in steroid dependent adult asthma patients and has rarely been reported in pediatric asthma patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!